Brief: Cutia Therapeutics Posts Q2 Revenue Of Group's Commercialized Products Of Rmb21.0 Mln
02/08/2023 02:35
Aug 2 (Reuters) - Cutia Therapeutics 2487.HK :
* Q2 REVENUE OF GROUP'S COMMERCIALIZED PRODUCTS RMB21.0
MILLION,
REPRESENTING A GROWTH OF 10,400%
Further company coverage: 2487.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China